Form 4: Centessa Pharmaceuticals Executive Tia L. Bush Executes Stock Transactions
SEC Form 4 Filing
Centessa Pharmaceuticals' Chief Technology & Quality Officer, Tia L. Bush, engaged in multiple stock transactions, including sales and option exercises, according to a recent SEC filing.
Summary
- Tia L. Bush, Chief Technology & Quality Officer at Centessa Pharmaceuticals, executed several transactions involving the company's ordinary shares.
- On December 16, 2024, she sold 9,611 shares at a weighted average price of $16.3621 per share.
- On December 17, 2024, she exercised options to acquire 17,813 shares at $3.85 per share.
- Also on December 17, 2024, she sold 17,813 shares at $18 per share.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 14, 2024.
- Following these transactions, Ms. Bush directly owns 147,615 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive. It doesn't indicate any positive or negative sentiment, it is a neutral event.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry. Such transactions are often part of pre-planned trading strategies.
Comparison to Industry Standards
- Executive stock transactions are a common occurrence in publicly traded companies, particularly in the pharmaceutical sector.
- The use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.
- Comparable companies such as BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated also see similar filings from their executives.
Stakeholder Impact
- The transactions may have a minor impact on the stock price, but are unlikely to cause significant fluctuations.
- Shareholders may be interested in the details of executive stock transactions for transparency.
Key Dates
| Date | Description |
|---|---|
| 09/14/2024 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 12/16/2024 | Date of the first reported sale of ordinary shares. |
| 12/17/2024 | Date of the option exercise and subsequent sale of ordinary shares. |
| 02/01/2033 | Expiration date of the share options. |
Keywords
Centessa Pharmaceuticals, Tia L. Bush, stock transactions, SEC Form 4, Rule 10b5-1, insider trading, executive stock sales, share options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.